What’s on fire this morning 🔥

Check out the hottest plays this morning                                                                                                                                                                                                                                                                                                                                                                                                                 [header] Together with Tech Market Reporter Hey there, 360! Here are our top investing ideas today - these setups look primed! Be the best prepared trader on the Street. And don't forget to check out out Market Calendar, including lots of company earnings today and Top Headlines. [focus list] ACON - Up over 100% in pre-market on data showing improved surgical outcomes for lower back pain by its augmented intelligence platform EYPT - Closed up over 58% after $33 price target from Baird SFR - Continues higher on no news after 200% move Friday *A Message on Behalf of Tech Market Reporter 🔥Hot Stock of the Day 🔥 BYND Cannasoft Enterprises (Nasdaq: BCAN) We have a light week of economic data ahead of us, but massive earnings reports from AMZN, GOOGL, META, MSFT, etc. are going to have a big impact on markets this week. There is one trading idea that we have identified which has started to break out over the last few days, but it still looks like it is in the early stages. From a technical point of view, [this is an ideal stock to watch this week](. That stock is BYND Cannasoft Enterprises (Nasdaq: BCAN). Here are some great points to consider when looking at BCAN right now: - BCAN is a low-priced stock (it only trades around $2) - BCAN is a very [low-float stock]( (only around 2 million shares), and some “low-floats” have been delivering phenomenal returns lately - BCAN has a [high level of insider ownership]( (around 64% of shares are held by insiders) - BCAN is triggering a technical breakout right now, as it is starting to trade above key indicators BCAN has a history of violent spikes higher, as shown in the recent trading chart below… Of course, make sure you spend some time getting to know about the risks and potential rewards with any stock you trade and are comfortable with it. To get started, [check out this short report]( that our friends at Tech Market Reporter have put together. Remember, last week’s idea made a move of over 25% in the days following our alert. The week before that, our top idea delivered over a 90% move. Be sure you keep a close eye on BCAN this week… you’ll be glad you did! *Sponsored by Lifewater Media. Please see disclosures below. [hotlist] ACON - Up over 100% in pre-market on data showing improved surgical outcomes for lower back pain by its augmented intelligence platform Aclarion (ACON) is the AI play this morning. The company announced data showing improved surgical outcomes for discogenic low back pain surgeries at chemically painful lumbar discs identified by Nociscan, touted as the first augmented intelligence platform to measure pain biomarkers in the lumbar spine. Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07). The $1.30 area was resistance in the pre-market and should be an important pivot level this morning. Above it, targets to the upside are at $1.40, $1.50 with the pre-market high at $1.67. Beyond that, there is resistance at $1.77, $1.90, $2 with $2.30, $2.40 and $2.50 above that. Below $1.30, there is potential support at $1.15, $1 and then a gap to fill at $0.7399. EYPT - Closed up over 58% after $33 price target from Baird Eyepoint Pharmaceuticals (EYPT) received an outperform rating and $33 price target from Baird in the after-hours Thursday, and that was enough to send the stock up over 58% on Friday. The stock was already strong into the news and the upgrade was enough for an explosive day. The stock closed at $9 so there is still plenty of action to both the upside and downside for active traders in the stock this morning. $8.20 was a consolidation area on Friday and should be an important pivot point today. Above it, targets to the upside are $8.60, $9.20, $9.50, $10, and then Friday’s high of $10.41. Beyond that, $11, $12 and $13 come into play. Below $8.20, targets to the downside are at $7.80, $7.30, with $6 and $5.50 below that. SFR - Continues higher on no news after 200% move Friday Appreciate Holdings (SFR) is up over 30% in pre-market trade after closing up over 200% on Friday on no news. Perhaps the move on news has some short sellers stuck who might have thought that a move on no news should reverse. Stuck short sellers could be adding more fuel to the move higher this AM. The $1.96 level was resistance in the after-hours and acted as support in the pre-market so is an important level to watch. Above it, targets to the upside are at $2.25, $2.35, with $2.50 and $2.73 above that. Beyond that, $3.50 and $3.80 come into play with $5 and $6 next. Below $1.96, there is potential support at $1.70 and $1.60 with $1.10 and the $1 magnet below that. Economic Calendar (EST) 8:30 am Chicago fed index 10:30 am Dallas Fed Mfg survey No Fed Speakers scheduled Earnings for Today (After Market) AAN, AGNC, AMP, ARE, BRO, CADE, CCK, CDNS, CHX, CLF, CNI, DALN, EFSC, FRC, FSBC, HLX, HMST, HOPE, HSII, HSTM, HTLF, HXL, IBTX, KREF, MEDP, NBN, NBR, NBTB, NBTX, NTB, PCH, PKG, RBB, RRC, SEVN, SMBK, SSD, TBI, TENB, TRST, WHR, WSBC, WSFS Top Headlines IDYA IDYA - IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma ADVM Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec TSLA Tesla Readies Export Of Model Y To Canada From China – RTRS AAPL Goldman expects better-than-anticipated results from Apples (AAPL) iPhone CTRM Castor Maritime receives Nasdaq receipt for non compliance LMT Lockheed Martin bags $2.45B Army contract modification QH Quhuo Announces Partnership to Utilize Search Giant Baidu's Recently Unveiled AI-Powered ERNIE Bot TRIB Global Transport Media Market Outlook & Forecasts Report 2023: A $12.59 Billion Market by 2028 - Rapid Acceleration of Diagnostics Increasing Prevalence of Infectious Diseases Bolsters Growth TPC Black Construction Awarded $222 Million Tinian International Airport Project AXNX Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation QH BIDU Quhuo Announced Partnership to Utilize Search Giant Baidus Recently Unveiled AI-Powered ERNIE Bot TSLA Expect To Continue To Generate Net Positive Operating Cash Flow As We Have Done In The Last Four Fiscal Years ADBE Adobe expands India operations with new 2,000-seat office in Bengaluru – Bloomberg DSGN: Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 ANIP: ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP BRTX: BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100 CANF Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization OTEX: OpenText World EMEA gets underway, unveiling the newest Cloud Editions Innovations and reimagining the Future of Information Management DNA Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production IONS: Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks BCLI BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer UNCY: Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress RYTM: Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome APLT: Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission APLT: Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity KRYS: Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program AZN: NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks BLCO: Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System TLSA: Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule ASLN: ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting GILT Intelsat Strengthens Strategic Partnership and Expands Service Capabilities with Significant Multimillion-Dollar Orders for Gilat's Multi-service Platforms and Terminal To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising BYND Cannasoft Enterprises from a period beginning on April 24, 2023 through April 25 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in BYND Cannasoft Enterprises. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of BYND Cannasoft Enterprises., increased trading volume, and possibly an increased share price of the BYND Cannasoft Enterprises securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](